Comparative Pharmacology
Head-to-head clinical analysis: OXCARBAZEPINE versus PARADIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXCARBAZEPINE versus PARADIONE.
OXCARBAZEPINE vs PARADIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilization of neuronal membranes by blockade of voltage-sensitive sodium channels, leading to inhibition of repetitive firing and reduction of neurotransmitter release.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Initial 300 mg orally twice daily; increase by 300 mg/day every third day to target dose of 600-1200 mg/day in two divided doses. Maximum 2400 mg/day.
100 mg orally three times daily; maximum 600 mg/day.
None Documented
None Documented
Clinical Note
moderateOxcarbazepine + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Cobicistat
"The serum concentration of Cobicistat can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Saxagliptin
Oxcarbazepine: 2 hours (parent drug); MHD (active metabolite): 9 hours. Steady-state achieved in 2-3 days. Context: shorter t1/2 than carbamazepine; MHD t1/2 extended in renal impairment (up to 19 hours).
12-24 hours (terminal); prolonged in renal impairment
Renal: 70% (mainly as glucuronide metabolites, unchanged drug <1%). Fecal: negligible.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Saxagliptin can be decreased when it is combined with Oxcarbazepine."